FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2555143489> ?p ?o ?g. }

• W2555143489 abstract "Abstract Reduced toxicity ablative conditioning regimens are increasingly used for allogeneic stem cell transplantation (allo-SCT). The impact of early donor cell chimerism on outcomes of T cell–replete reduced-intensity conditioning SCT in myeloid disorders is ill defined. To explore the impact of measuring busulfan pharmacokinetics in conditioning regimens on early donor chimerism, we undertook a retrospective analysis of patients with myeloid disorders who received four days of fludarabine and busulfan with or without measuring busulfan pharmacokinetics at our center in the last 10 years. Methods: Chimerism assay was performed using a quantitative fluorescence-based short tandem repeat– polymerase chain reaction (STR-PCR) with capillary electrophoresis for PCR product resolution. Results: Thirty patients were identified and included in the analysis. All patients were conditioned with fludarabine (40 mg/m2/day x 4 doses), busulfan (3.2mg/kg/dose IV x 4 doses). Of these thirty patients, 7 had busulfan pharmacokinetics measured. There were 21 male and 9 female patients with a median age of 62 years (range 48–72yrs). Median time to follow up was 13.3 months. Diagnoses included AML (N=17), MDS (N=10), MPN (N=1), CMML (N=2). Disease risk was considered advanced in 17 patients, intermediate in 3 and early in 10. All patients in the busulfan pharmacokinetic group had advanced disease except one had early disease. Regarding cytogenetics, all patients in the busulfan pharmacokinetics group had high or intermediate risk cytogenetics. Median blast number at time of SCT was 5%. Stem cell source included peripheral blood in all patients. Eleven patients received matched related donor (MRD) SCT, 15 had matched unrelated donor (MUD) SCT and 4 had mismatched unrelated donor (MMUD) SCT. Prophylaxis of GVHD consisted of tacrolimus and methotrexate in MRD, and tacrolimus, methotrexate and anti-thymocyte globulin in MUD and MMUD. All patients engrafted neutrophils and platelets promptly (median 13 and 14 days, respectively). There were no primary graft failures. Total Donor cell Chimerism analysis in the Busulfan pharmacokinetics group showed 100% donor at both time points (days 30, 100) in all patients except in one who relapsed at day 30 (85.7%). While in the non-pharmacokinetics group only 7 out of 23 (30%) patients had complete chimerism at day 30 and day 100. Complete donor chimerism at day 100 in the non-pharmacokinetics group was 47.8% compared to 85.7% in the pharmacokinetic group (p=0.18). Ten out of 23 patients (43.5%) in the non-pharmacokinetics group had decreasing donor chimerism by day 100, while in the pharmacokinetic group only one patient (14%) who relapsed had decreasing donor chimerism by day 100 with an odds ratio of 0.241 (95% Confidence Interval =0.025-2.357; p-value=0.22). None developed sinusoidal obstructive syndrome. Conclusion: In this small cohort of consecutive patients from a single center, we found that patients with myeloid disorders who received fludarabine busulfan for 4 days incorporating busulfan pharmacokinetics had a trend for higher rates of early complete donor chimerism and less decreasing donor chimerism by day100, although not statistically significant, despite having intermediate or high risk disease at time of SCT. Longer follow up is needed for our patients to see if there is effect on relapse or survival but previous studies have showed that low or decreasing donor chimerism early after SCT is an independent risk factor for relapse and impaired survival. This is especially important in myeloid disorders. Busulfan pharmacokinetics may help target better level for inducing early total donor chimerism and donor chimerism may identify high-risk patient cohorts who may benefit from additional therapeutic interventions. These results should be interpreted with caution given the retrospective design of the study and the small number of patients. Disclosures No relevant conflicts of interest to declare." @default.
• W2555143489 created "2016-11-30" @default.
• W2555143489 creator A5000681901 @default.
• W2555143489 creator A5030931835 @default.
• W2555143489 creator A5032423630 @default.
• W2555143489 creator A5038619610 @default.
• W2555143489 creator A5038695041 @default.
• W2555143489 creator A5050616552 @default.
• W2555143489 creator A5057521754 @default.
• W2555143489 creator A5075757306 @default.
• W2555143489 creator A5076082845 @default.
• W2555143489 creator A5090835650 @default.
• W2555143489 date "2014-12-06" @default.
• W2555143489 modified "2023-10-11" @default.
• W2555143489 title "High Rates of Early Donor Chimerism in Intermediate and Poor Risk Patients Undergoing Stem Cell Transplantation Using Reduced Toxicity Ablative Conditioning Regimen Incorporating Busulfan Pharmacokinetics" @default.
• W2555143489 doi "https://doi.org/10.1182/blood.v124.21.3874.3874" @default.
• W2555143489 hasPublicationYear "2014" @default.
• W2555143489 type Work @default.
• W2555143489 sameAs 2555143489 @default.
• W2555143489 citedByCount "0" @default.
• W2555143489 crossrefType "journal-article" @default.
• W2555143489 hasAuthorship W2555143489A5000681901 @default.
• W2555143489 hasAuthorship W2555143489A5030931835 @default.
• W2555143489 hasAuthorship W2555143489A5032423630 @default.
• W2555143489 hasAuthorship W2555143489A5038619610 @default.
• W2555143489 hasAuthorship W2555143489A5038695041 @default.
• W2555143489 hasAuthorship W2555143489A5050616552 @default.
• W2555143489 hasAuthorship W2555143489A5057521754 @default.
• W2555143489 hasAuthorship W2555143489A5075757306 @default.
• W2555143489 hasAuthorship W2555143489A5076082845 @default.
• W2555143489 hasAuthorship W2555143489A5090835650 @default.
• W2555143489 hasConcept C112705442 @default.
• W2555143489 hasConcept C126322002 @default.
• W2555143489 hasConcept C141071460 @default.
• W2555143489 hasConcept C143998085 @default.
• W2555143489 hasConcept C2776694085 @default.
• W2555143489 hasConcept C2776755627 @default.
• W2555143489 hasConcept C2777408962 @default.
• W2555143489 hasConcept C2779263901 @default.
• W2555143489 hasConcept C2780611847 @default.
• W2555143489 hasConcept C2911091166 @default.
• W2555143489 hasConcept C71924100 @default.
• W2555143489 hasConcept C90924648 @default.
• W2555143489 hasConceptScore W2555143489C112705442 @default.
• W2555143489 hasConceptScore W2555143489C126322002 @default.
• W2555143489 hasConceptScore W2555143489C141071460 @default.
• W2555143489 hasConceptScore W2555143489C143998085 @default.
• W2555143489 hasConceptScore W2555143489C2776694085 @default.
• W2555143489 hasConceptScore W2555143489C2776755627 @default.
• W2555143489 hasConceptScore W2555143489C2777408962 @default.
• W2555143489 hasConceptScore W2555143489C2779263901 @default.
• W2555143489 hasConceptScore W2555143489C2780611847 @default.
• W2555143489 hasConceptScore W2555143489C2911091166 @default.
• W2555143489 hasConceptScore W2555143489C71924100 @default.
• W2555143489 hasConceptScore W2555143489C90924648 @default.
• W2555143489 hasLocation W25551434891 @default.
• W2555143489 hasOpenAccess W2555143489 @default.
• W2555143489 hasPrimaryLocation W25551434891 @default.
• W2555143489 hasRelatedWork W2323358904 @default.
• W2555143489 hasRelatedWork W2509833577 @default.
• W2555143489 hasRelatedWork W2549796584 @default.
• W2555143489 hasRelatedWork W2552341902 @default.
• W2555143489 hasRelatedWork W2563872108 @default.
• W2555143489 hasRelatedWork W2564904999 @default.
• W2555143489 hasRelatedWork W2568833872 @default.
• W2555143489 hasRelatedWork W2575845066 @default.
• W2555143489 hasRelatedWork W2582662296 @default.
• W2555143489 hasRelatedWork W2585617225 @default.
• W2555143489 hasRelatedWork W2588687684 @default.
• W2555143489 hasRelatedWork W2590830408 @default.
• W2555143489 hasRelatedWork W2599243698 @default.
• W2555143489 hasRelatedWork W2914966618 @default.
• W2555143489 hasRelatedWork W2980248948 @default.
• W2555143489 hasRelatedWork W2980718349 @default.
• W2555143489 hasRelatedWork W3001019721 @default.
• W2555143489 hasRelatedWork W3035235183 @default.
• W2555143489 hasRelatedWork W3096751439 @default.
• W2555143489 hasRelatedWork W869527191 @default.
• W2555143489 isParatext "false" @default.
• W2555143489 isRetracted "false" @default.
• W2555143489 magId "2555143489" @default.
• W2555143489 workType "article" @default.